{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:14:06Z","timestamp":1788930846958,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.autrev.2023.103503","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T16:54:48Z","timestamp":1702486488000},"page":"103503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1016","volume":"23","author":[{"given":"Federica","family":"Davanzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bortoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.autrev.2023.103503_bb0005","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"2022 American College of Rheumatology\/European Alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with Polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103503_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.alit.2021.02.002","article-title":"Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media","volume":"70","author":"Hamada","year":"2021","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.autrev.2023.103503_bb0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.alit.2021.11.003","article-title":"Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis","volume":"71","author":"Anai","year":"2022","journal-title":"Allergol Int Off J Jpn Soc Allergol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103503_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100707","article-title":"Combining biologics targeting eosinophils (IL-5\/IL-5R), IgE, and IL-4\/IL-13 in allergic and inflammatory diseases","volume":"15","author":"Pitlick","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"9","key":"10.1016\/j.autrev.2023.103503_bb0025","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/all.15379","article-title":"Safety of combining biologics in severe asthma: asthma-related and unrelated combinations","volume":"77","author":"Lommatzsch","year":"2022","journal-title":"Allergy."},{"issue":"10","key":"10.1016\/j.autrev.2023.103503_bb0030","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1016\/j.jaip.2020.06.052","article-title":"Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab","volume":"8","author":"Galant-Swafford","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.autrev.2023.103503_bb0035","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.jaip.2021.07.049","article-title":"Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP","volume":"9","author":"Briegel","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.autrev.2023.103503_bb0040","article-title":"Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma","volume":"79","author":"Descamps","year":"2021","journal-title":"Respir Med Res"},{"issue":"3","key":"10.1016\/j.autrev.2023.103503_bb0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anai.2019.06.013","article-title":"Combination biologic therapy for severe persistent asthma","volume":"123","author":"Ortega","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103503_bb0050","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/ard.54.7.604","article-title":"Pregnancy in granulomatous vasculitis","volume":"54","author":"Lima","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"5 Supplement","key":"10.1016\/j.autrev.2023.103503_bb0055","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.anai.2018.09.297","article-title":"Combination biologic therapy in severe asthma: a CASE series","volume":"121","author":"Thomes","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2023.103503_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.587621","article-title":"Dual monoclonal antibody therapy for a severe asthma patient","volume":"11","author":"Domingo","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103503_bb0065","first-page":"306","article-title":"Combination anti-IgE and anti-IL5 therapy in a pediatric patient with severe persistent asthma","volume":"26","author":"Fox","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.autrev.2023.103503_bb0070","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.anai.2017.08.272","article-title":"P234 combination omalizumab and mepolizumab therapy for poorly-controlled severe persistent asthma","volume":"119","author":"Tongchinsub","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103503_bb0075","first-page":"473","article-title":"Case study: a combination of Mepolizumab and Omaluzimab injections for severe asthma","volume":"56","author":"Dedaj","year":"2019","journal-title":"J Asthma Off J Assoc Care Asthma"},{"issue":"10","key":"10.1016\/j.autrev.2023.103503_bb0080","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.jaip.2021.06.033","article-title":"Effect of dupilumab treatment in a severe asthma patient with EGPA","volume":"9","author":"Matucci","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"18","key":"10.1016\/j.autrev.2023.103503_bb0085","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of Itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103503_bb0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T06:29:00Z","timestamp":1715063340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223002379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1568997223002379"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103503","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103503"}}